手霉素A
Manumycin A
- 产品特性
- 相关资料
- Q&A
- 参考文献
Manumycin A
手霉素A
◆产品规格/储存说明
产品详情
产品类型：生化试剂
产品特性
分子式：C31H38N2O7
分子量：550.6
CAS：52665-74-4
来源：从海洋放线菌（Streptomyces parvulus）中分离
纯度：≥98%（HPLC）
外观：黄色~棕色粉末
溶解性：溶于DMSO或甲醇，不溶于水
检测方式：经1H-NMR检测
InChi Key：TWWQHCKLTXDWBD-MVTGTTCWSA-N
Smiles：
CCCC[C@@H](C)C=C(/C)C=C(/C)C(=O)NC1=C[C@@](O)(C=CC=CC=CC(=O)NC2=C(O)CCC2=O)[C@@H]2O[C@@H]2C1=O
运输/储存条件
运 输：干冰运输
短期储存温度：+4°C
长期储存温度：-20°C
建议储存条件：避光
使用事项/稳定性：自生产后在-20°C下至少可稳定储存1年；溶解后避光储存于-20°C下。
◆产品应用
● 抗生素。
● 凋亡和内质网应激介导的细胞死亡诱导剂。
● 高效、高选择性、高竞争性的细胞渗透性ras法尼基转移酶（rasfarnesyltransferase）抑制剂（IC50=30 nM ）。
● 不影响香叶基香叶基转移酶（IC50 = 180 µM）。
● 对法尼基焦磷酸具有竞争性抑制作用，而对Ras的抑制作用为非竞争性。
● 中性鞘磷脂酶抑制剂。
● 阻断大鼠心肌细胞中胰岛素诱导的MAP激酶的激活（19 μM）。
● 靶向蛋白磷酸酶1α（PP1α），并还原过氧化氢。
● 纠正强直性肌营养不良1型（DM1）中肌肉氯离子通道Clcn1的异常剪接。
● 表现出潜在的抗炎活性。
● 不可逆的人硫氧还蛋白还原酶1（TrxR-1）抑制剂（IC50=272 nM）和NADPH氧化酶活性诱导剂。其很可能充当TrxR-1 C端氧化还原中亲核
● Sec残基的Michael受体，并产生SecTRAP（硒损害硫氧还蛋白还原酶来源凋亡蛋白），该蛋白通过氧化应激同时促进细胞凋亡、坏死，增加细
● 胞内活性氧（ROS）的产生。
● 由于外泌体释放过程中有Ras的参与，证实了手霉素A是一种外泌体分泌的抑制剂。
● 可治疗强直性肌营养不良1型（DM1）。
● 通过靶向蛋白磷酸酶1α 介导淋巴瘤细胞凋亡。
◆产品列表
|
产品编号 |
产品名称 |
包装 |
|
BVT-0091-M001 |
Manumycin A |
1 mg |
|
BVT-0091-M005 |
5 mg |
|
|
BVT-0091-M010 |
10 mg |
相关产品
|
产品编号 |
产品名称 |
包装 |
|
BVT-0414 |
Dihydromanumycin A |
1 mg |
|
BVT-0264 |
Manumycin B |
1 mg |
|
BVT-0158 |
Deoxymanumycin A |
1 mg |
|
BVT-0139 |
Rebeccamycin |
250 μg |
|
1 mg |
||
|
BVT-0100 |
Chrysomycin B |
250 μg |
|
1 mg |
||
|
BVT-0099 |
Chrysomycin A |
250 μg |
|
1 mg |
||
|
BVT-0095 |
Pyrrolcarbonyltaloside |
1 mg |
|
BVT-0070 |
Mutolide |
1 mg |
※ 本页面产品仅供研究用，研究以外不可使用。
参考文献
|
1. |
Identification of Rasfarnesyltransferase inhibitors by microbial screening: M. Hara et al.; PNAS 90, 2281 (1993) |
|
2. |
Inhibitors of Rasfarnesyltransferases: F. Tamanoi; TIBS 18, 349 (1993), (Review) |
|
3. |
Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic: J.B. Gibbs, et al.; Cell 77, 175 (1994) |
|
4. |
Protein kinase C, but not tyrosine kinases or Ras, plays a critical role in angiotensin II-induced activation of Raf-1 kinase and extracellular signal-regulated protein kinases in cardiac myocytes: Y. Zou et al.; J. Biol. Chem. 271, 33592 (1996) |
|
5. |
Manumycin inhibits ras signal transduction pathway and induces apoptosis in COLO320-DM human colon tumour cells: A. Di Paolo, et al.; Br. J. Cancer 82, 905 (2000) |
|
6. |
Manumycin A and its analogues are irreversible inhibitors of neutral sphingomyelinase: C. Arenz, et al.; ChemBioChem 2, 141 (2001) |
|
7. |
Enhancement of manumycin A-induced apoptosis by methoxyamine in myeloid leukemia cells: M. She, et al.; Leukemia 19, 595 (2005) |
|
8. |
Binding of manumycin A inhibits IkappaB kinase beta activity: M. Bernier, et al.; J. Biol. Chem. 281, 2551 (2006) |
|
9. |
A yeast-based genomic strategy highlights the cell protein networks altered by FTase inhibitor peptidomimetics: G. Porcu, et al.; Mol. Cancer 9:197 (2010) |
|
10. |
Targeting farnesyl-transferase as a novel therapeutcstrategy for mevalonate kinase defiency: In vitro and in vivo approaches: L. De Leo, et al.; Pharmacol. Res. 61, 506 (2010) |
|
11. |
Manumycin A corrects aberrant splicing of Clcn1 in myotonic dystrophy type 1 (DM1) mice: K. Oana, et al.; Sci. Rep. 3, 2142 (2013) |
|
12. |
Manumycin induces apoptosis in prostate cancer cells: J.G. Li, et al., Onco Targets Ther. 7, 771 (2014) |
|
13. |
The natural tumorcide Manumycin-A targets protein phosphatase 1α and reduces hydrogen peroxide to induce lymphoma apoptosis. G.B. Carey, et al.; Exp. Cell. Res. 332, 136 (2015) |
|
14. |
Manumycin A from a new streptomyces strain induces endoplasmic reticulum stress-mediated cell death through specificity protein 1 signaling in human oral squamous cell carcinoma: C.J. Jae, et al.; Int. J. Oncol. 47, 1954 (2015) |
|
15. |
Manumycin A downregulates release of proinflammatory cytokines from TNF alpha stimulated human monocytes: E. Cecrdlova, et al.; Immunol. Lett. 169, 8 (2016) |
|
16. |
Manumycin A suppresses exosome biogenesis and secretion via targeted inhibition of Ras/Raf/ERK1/2 signaling and hnRNP H1 in castration-resistant prostate cancer cells: A. Datta, et al.; Cancer Lett. 408, 73 (2017) |
|
17. |
Manumycin A Is a Potent Inhibitor of Mammalian Thioredoxin Reductase-1 (TrxR-1): A. Tuladhar & K.S. Rein; ACS Med. Chem. Lett. 9, 318 (2018) |
|
18. |
The free fatty acid receptor 1 promotes airway smooth muscle cell proliferation through MEK/ERK and PI3K/Akt signaling pathways: A. Matoba, et al.; Am. J. Physiol. 314, 333 (2018) |
|
19. |
Effectors of thioredoxin reductase: Brevetoxins and manumycin-A: A. Tuladhar, et al.; Comp. Biochem. Physiol. C Toxicol. Pharmacol. 217, 76 (2019) |
|
20. |
Inhibiting extracellular vesicles formation and release: a review of EV inhibitors: M. Catalano & L. O'Driscoll; J. Etracell. Vesicles 9, 1703244 (2020) |
|
21. |
Combination of photoactive hypericin and Manumycin A exerts multiple anticancer effects on oxaliplatin-resistant colorectal cells: M. Macejova, et al.; Toxicol. Vitro 66, 104860 (2020) |
|
|